All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
In April 2018, Francesco Zaja from the University of Udine, Italy, and colleagues published ahead of print in Leukemia and Lymphoma, a phase II clinical trial on panobinostat for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), on behalf of the Italian Lymphoma Foundation (Fondazione Italiana Linfomi).
The aim of the study was to evaluate the efficacy and safety of oral panobinostat (PAN) administration for the treatment of heavily pre-treated R/R DLBCL patients, who have received at least two previous regimens including rituximab-containing therapies and ASCT if they were eligible for it. The primary endpoint of this study was overall response rate (ORR) following induction phase completion, with secondary endpoints including progression-free survival (PFS), overall survival (OS), response duration (RD), time to response (TTR) and safety.
These results demonstrate than PAN has a modest activity in R/R DLBCL patients and that treatment-related toxicities like thrombocytopenia limit the use of this regimen. The authors noted that with the development of better biological markers associated with PAN response, the identification of a certain DLBCL patient subgroup that might benefit from this treatment will be feasible.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox